Novo Nordisk sues Eli Lilly over comparative obesity drug advertising
The New Jersey federal suit alleges Lilly used older clinical trials to claim its diabetes and weight-loss treatments are more effective.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 29 03:00 ETSource: Law Commentary
The wire
- 01Novo Nordisk filed suit Tuesday in U.S. District Court in New Jersey challenging national advertising campaigns comparing Lilly's weight-loss and diabetes drugs with Novo's.
- 02The complaint alleges Lilly misled consumers by relying on older trial data, putting incretin marketing claims that clinicians and patients see directly in front of a court.
- 03Lilly's response and any ruling are pending; the allegations are unproven.
From the source
Read at lawcommentary.comNovo Nordisk Must Face Investor Fraud Claims Over CagriSema Trial Disclosures
Novo Nordisk has sued Eli Lilly over national advertising campaigns for the companies' competing weight loss and diabetes drugs, alleging that Lilly is misleading consumers by using older clinical trials to claim its treatments are more effective.The lawsuit, filed Tuesday in U.S. District Court in New Jersey, challenges advertisements comparing... Read More »